Showing results (1-10 of 40) with videos related to
Sort By:
Pageof 4
Anticancer Research|June 25, 2003
HER-2/neu determination in blood plasma of patients with HER-2/neu overexpressing metastasized breast cancer: a longitudinal studyMarkus Hoopmann, Rainer Neumann, Thérese Tanasale, et al.Journal of Diabetes Science and Technology|June 2, 2010
High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazoneAndreas Pfützner, Thomas Schöndorf, Markolf Hanefeld, et al.Clinical Laboratory|November 16, 2005
Biological background and role of adiponectin as marker for insulin resistance and cardiovascular riskThomas Schöndorf, Agnes Maiworm, Neil Emmison, et al.Journal of Diabetes Science and Technology|November 6, 2009
Self-monitoring of blood glucose levels requires intensive training for use of meters to obtain reliable and clinically relevant measurementsThomas A Mohr, Andreas Pfützner, Senait Forst, et al.Diabetes & Vascular Disease Research|April 13, 2010
Increased prevalence of cardiovascular disease and risk biomarkers in patients with unknown type 2 diabetes visiting cardiology specialists: results from the DIASPORA studyThomas Schöndorf, Georg Lübben, Efstrathios Karagiannis, et al.Journal of Diabetes Science and Technology|November 4, 2009
Pioglitazone improves metabolic markers in patients with type 2 diabetes independently from physical activities: results from the IRIS III studyThomas Schöndorf, Andreas Pfützner, Georg Lübben, et al.Diabetes Technology & Therapeutics|May 23, 2009
Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in type 2 diabetes patients with insufficient glycemic control by metformin alone--results from a post-marketing surveillance trial under daily routine conditionsThomas Schöndorf, Efstrathios Karagiannis, Richard E K Posseldt, et al.Cancer Letters|October 3, 2002
Tumor M2 pyruvate kinase--determination in breast cancer patients receiving trastuzumab therapyMarkus Hoopmann, Mathias Warm, Peter Mallmann, et al.Oncology Reports|October 11, 2002
Lack of prognostic significance of nm23 expression in human primary breast cancerUwe-Jochen Göhring, Ira Eustermann, Martina Becker, et al.Metabolism: Clinical and Experimental|December 6, 2005
Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepirideAndreas Pfützner, Thomas Schöndorf, Daniela Seidel, et al.Pageof 4